Aflibercept for Retinopathy of Prematurity : A Systematic Review and Meta-Analysis
BACKGROUND AND OBJECTIVE: To determine the effectiveness of aflibercept in retinopathy of prematurity (ROP)
| Publié dans: | Ophthalmic surgery, lasers & imaging retina. - 2013. - 52(2021), 12 vom: 22. Dez., Seite 673-681 |
|---|---|
| Auteur principal: | |
| Autres auteurs: | , |
| Format: | Article en ligne |
| Langue: | English |
| Publié: |
2021
|
| Accès à la collection: | Ophthalmic surgery, lasers & imaging retina |
| Sujets: | Journal Article Meta-Analysis Systematic Review Angiogenesis Inhibitors Recombinant Fusion Proteins Vascular Endothelial Growth Factor A aflibercept 15C2VL427D Receptors, Vascular Endothelial Growth Factor EC 2.7.10.1 |
| Résumé: | BACKGROUND AND OBJECTIVE: To determine the effectiveness of aflibercept in retinopathy of prematurity (ROP) PATIENTS AND METHODS: We performed a systematic review and meta-analysis of proportions from the literature in PubMed and Cochrane Library using search terms related to the use of aflibercept in ROP. Studies in non-preterm infants or that did not use aflibercept as the initial treatment were excluded. Risk of bias was assessed by the ROBINS-I (Risk Of Bias in Non-randomized Studies of Interventions) tool RESULTS: We identified six case series. Collectively, 218 eyes were treated with aflibercept for ROP. We found an average 97% (95% confidence interval [CI], 93% to 99%) regression rate with aflibercept and an average 16% (95% CI, 5% to 41%) recurrence rate. With the exception of one outlier study, these numbers are similar to previous reports using anti-vascular endothelial growth factor (VEGF) agents in ROP CONCLUSIONS: Aflibercept holds promise for use in ROP and has been demonstrated to be efficacious in six case series. Randomized, controlled clinical trials appear warranted to compare aflibercept with other anti-VEGF agents. [Ophthalmic Surg Lasers Imaging. 2021;52:673-681.] |
|---|---|
| Description: | Date Completed 08.04.2022 Date Revised 08.04.2022 published: Print-Electronic Citation Status MEDLINE |
| ISSN: | 2325-8179 |
| DOI: | 10.3928/23258160-20211124-01 |